Clinical Genomicist WorkSpace (CGW)
WELCOME TO YOUR WORKSPACE.
Streamlined Integrated Workflow
The Clinical Genomicist Workspace (CGW) is our comprehensive environment that will accelerate your ability to offer Next Generation Sequencing-based clinical tests. Our cloud-based single workspace solution seamlessly manages data and clinical workflow for each patient case:
Sequencing: primary data are acquired from sequencers to start the analytical process
Analysis: variants are called and annotated using validated pipelines and comprehensive genomic databases
Draft Report: medical interpretations and just-in-time curated information from our rapidly expanding medical knowledgebase are processed through a proprietary algorithm, which then produces a report highlighting the most relevant, clinically actionable information
Final Report: a fully featured, online editing system allows the medical professional to review, finalize, and sign out a report
Integration in Electronic Health Record: signed out report is messaged to the medical record for review by the treating physician
RAMP UP YOUR NGS TESTING
The PierianDx NGS Gateway Program allows you to access and customize a range of NGS assays right out of the box utilizing subsets customized from 131 different genes. This program delivers clinically validated Next-Generation Sequencing (NGS) tests for solid tumors, hematopoietic disorders, central nervous system tumors, melanoma and more. The NGS Gateway Program:
Enhances your brand by making personalized medicine your competitive advantage
Eases transition into fully-integrated NGS lab capabilities
No capital outlay to get started
Provides speed to market – you focus on your long-term NGS testing strategy while we help you implement today
GATEWAY PROGRAM ASSAYS
This 559-gene tumor panel covers immediately actionable mutations for somatic cancer. Reports include lists of somatic and germline variants, expression levels, available immunotherapies, and phenotypic and therapeutic information among other information.
Test includes total exonic coverage for somatic variants in 71 genes and reporting of fusion transcripts from 51 genes.
Test includes total exonic coverage for somatic variants in 361 genes and reporting of fusion transcripts from 308 genes.
This assay sequences the coding exons and ~20 bp of the non-coding (intronic) flanking regions of 28 genes associated with hereditary cancer. The report accurately detects small deletions and duplications but does not currently capture large deletions and rearrangements.
Test includes total exonic coverage for somatic variants arising in 65 genes and six selected translocations that are clinically actionable in a wide range of adenocarcinomas, squamous cell carcinomas, gliomas, sarcomas and melanomas.
Test includes total exonic coverage for somatic variants arising in 54 genes, including translocations involving MLL/KMT2A, that are clinically actionable in myeloid, lymphoid and mixed lineage leukemias. It also includes genes that can help establi
Designed specifically for tumors of the central nervous system, this test includes total exonic coverage for somatic variants arising in 24 genes.
Test includes total exonic coverage for somatic variants arising in 33 genes, including multiple melanoma-specific genes as well as some overlap with the Solid Tumor Gene Set.
WE’VE GOT YOUR BACK
PierianDx’s Professional Services ensure that you have everything you need to effectively manage the clinical NGS workflow and can begin case sign-out as rapidly as possible. Our team of genomicists can help you with everything from designing your own NGS testing strategy to final implementation of custom assays. We can help you design and validate your own custom gene panels and pipelines, set up your own CLIA-certified lab, and develop a comprehensive validation plan for each panel. Our professional services allows you to:
Accelerate your personalized medicine initiatives
Ease transition into fully-integrated NGS lab capabilities
Provide flexible engagement services designed around your needs
Leverage years of experience and best practices
PierianDx interpretation services includes a team of medical directors and variant scientists that leverage technology to assist CGW customers during implementation or as add-on service. Our interpretation services cover the full range of gene tests for inherited conditions and somatic cancer, and can be customized in three ways:
PDx variant analysis with your medical director performing review and sign out
PDx variant analysis, case preparation and medical review with your sign-out
PDx performs the entire service including variant analysis, case preparation, medical review and sign out
“Our partnership with PierianDx will supply healthcare systems’ in-house labs with a simpler and more integrated workflow. The PierianDx bioinformatics platform and testing services will ultimately speed the delivery of precision care to patients.”